TABLE 4

Mean ± SE (of four time points) of isotopic enrichment of phenylalanine and tyrosine in the arterial vein (A), femoral vein (FV), and hepatic vein (HV) at the baseline (150–180 min) and during the last 30 min (330–360 min) of the infusion (intervention)

[15N]phenylalanine
[15N]tyrosine
[2H4]tyrosine
AFVHVAFVHVAFVHV
NS
 Baseline10.73 ± 0.578.52 ± 0.348.51 ± 0.311.54 ± 0.111.27 ± 0.111.58 ± 0.1311.70 ± 0.489.15 ± 0.349.13 ± 0.40
 Intervention10.91 ± 0.488.95 ± 0.319.15 ± 0.331.44 ± 0.121.17 ± 0.131.58 ± 0.1412.40 ± 0.489.90 ± 0.259.99 ± 0.37
Ins
 Baseline10.87 ± 0.328.72 ± 0.148.61 ± 0.311.59 ± 0.101.28 ± 0.071.51 ± 0.0912.30 ± 0.669.71 ± 0.539.70 ± 0.63
 Intervention12.52 ± 0.4310.31 ± 0.219.88 ± 0.281.62 ± 0.071.24 ± 0.071.61 ± 0.0715.08 ± 0.6511.90 ± 0.5712.10 ± 0.54
LoAA/Ins
 Baseline10.88 ± 0.388.41 ± 0.478.72 ± 0.281.56 ± 0.061.26 ± 0.081.59 ± 0.0511.31 ± 0.918.70 ± 0.809.16 ± 0.71
 Intervention9.02 ± 0.577.67 ± 0.487.92 ± 0.401.42 ± 0.101.17 ± 0.081.56 ± 0.0711.90 ± 0.919.60 ± 0.799.86 ± 0.69
HiAA/Ins
 Baseline10.46 ± 0.428.36 ± 0.238.45 ± 0.341.47 ± 0.111.15 ± 0.071.47 ± 0.1312.00 ± 0.529.25 ± 0.379.35 ± 0.45
 Intervention6.50 ± 0.526.07 ± 0.476.09 ± 0.461.41 ± 0.101.26 ± 0.091.69 ± 0.1412.53 ± 1.0310.96 ± 0.849.72 ± 0.72
Som/AA
 Baseline10.87 ± 0.418.82 ± 0.318.22 ± 0.271.79 ± 0.131.39 ± 0.081.81 ± 0.1010.83 ± 0.889.34 ± 0.629.14 ± 0.75
 Intervention8.06 ± 0.297.39 ± 0.267.24 ± 0.261.69 ± 0.101.48 ± 0.062.10 ± 0.1312.52 ± 0.9210.94 ± 0.709.75 ± 0.67
Som/NS
 Baseline11.43 ± 0.288.91 ± 0.218.86 ± 0.171.64 ± 0.151.35 ± 0.101.57 ± 0.2112.92 ± 0.649.93 ± 0.389.87 ± 0.71
 Intervention12.13 ± 0.319.49 ± 0.249.85 ± 0.231.69 ± 0.151.23 ± 0.121.83 ± 0.2113.70 ± 0.7010.30 ± 0.3510.90 ± 0.68
  • Data given as molar percent excess.